JP5498396B2 - ヒスタミンｈ４受容体アンタゴニストとしての４−アミノピリミジン誘導体 - Google Patents

ヒスタミンｈ４受容体アンタゴニストとしての４−アミノピリミジン誘導体 Download PDF

Info

Publication number
JP5498396B2
JP5498396B2 JP2010538738A JP2010538738A JP5498396B2 JP 5498396 B2 JP5498396 B2 JP 5498396B2 JP 2010538738 A JP2010538738 A JP 2010538738A JP 2010538738 A JP2010538738 A JP 2010538738A JP 5498396 B2 JP5498396 B2 JP 5498396B2
Authority
JP
Japan
Prior art keywords
alkyl
formula
group
compound
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010538738A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011506566A (ja
JP2011506566A5 (enExample
Inventor
カルセリエール・ゴンサレス，エレナ
メデイナ・フエンテス，エバ・マリア
ソリバ・ソリバ，ロベルト
ビルヒリ・ベルナド，マリナ
マルテイ・ビア，ホセプ
Original Assignee
パラウ・フアルマ・ソシエダツド・アノニマ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パラウ・フアルマ・ソシエダツド・アノニマ filed Critical パラウ・フアルマ・ソシエダツド・アノニマ
Publication of JP2011506566A publication Critical patent/JP2011506566A/ja
Publication of JP2011506566A5 publication Critical patent/JP2011506566A5/ja
Application granted granted Critical
Publication of JP5498396B2 publication Critical patent/JP5498396B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2010538738A 2007-12-21 2008-12-18 ヒスタミンｈ４受容体アンタゴニストとしての４−アミノピリミジン誘導体 Active JP5498396B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07382006 2007-12-21
EP07382006.0 2007-12-21
US3153408P 2008-02-26 2008-02-26
US61/031,534 2008-02-26
PCT/EP2008/067950 WO2009080721A2 (en) 2007-12-21 2008-12-18 4 -aminopyrimidine derivatives as histamine h4 receptor antagonists

Publications (3)

Publication Number Publication Date
JP2011506566A JP2011506566A (ja) 2011-03-03
JP2011506566A5 JP2011506566A5 (enExample) 2012-02-02
JP5498396B2 true JP5498396B2 (ja) 2014-05-21

Family

ID=39473347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010538738A Active JP5498396B2 (ja) 2007-12-21 2008-12-18 ヒスタミンｈ４受容体アンタゴニストとしての４−アミノピリミジン誘導体

Country Status (24)

Country Link
US (1) US8431580B2 (enExample)
EP (1) EP2235012B1 (enExample)
JP (1) JP5498396B2 (enExample)
KR (1) KR101639819B1 (enExample)
CN (1) CN101903385B (enExample)
AR (1) AR069814A1 (enExample)
AU (1) AU2008341678B2 (enExample)
BR (1) BRPI0820779B8 (enExample)
CA (1) CA2709650C (enExample)
CL (1) CL2008003811A1 (enExample)
CY (1) CY1114427T1 (enExample)
DK (1) DK2235012T3 (enExample)
ES (1) ES2430210T3 (enExample)
HR (1) HRP20130918T1 (enExample)
IL (1) IL206413A (enExample)
PE (1) PE20091330A1 (enExample)
PL (1) PL2235012T3 (enExample)
PT (1) PT2235012E (enExample)
RU (1) RU2489430C2 (enExample)
SI (1) SI2235012T1 (enExample)
TW (1) TWI429440B (enExample)
UA (1) UA101963C2 (enExample)
WO (1) WO2009080721A2 (enExample)
ZA (1) ZA201005179B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
EA019320B1 (ru) 2008-12-22 2014-02-28 Мерк Патент Гмбх Новые полиморфные формы дигидрофосфата 6-(1-метил-1h-пиразол-4-ил)-2-{3-[5-(2-морфолин-4-илэтокси)пиримидин-2-ил]бензил}-2h-пиридазин-3-она и способы их получения
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
JP5759471B2 (ja) 2009-10-29 2015-08-05 ヴェクチュラ リミテッド Ｊａｋ３キナーゼ阻害剤としての窒素含有ヘテロアリール誘導体
JP5781537B2 (ja) * 2009-12-23 2015-09-24 メディシス ファーマシューティカル コーポレイション ヒスタミンｈ４受容体アンタゴニストとしてのアミノアルキルピリミジン誘導体
HUE039713T2 (hu) 2012-06-08 2019-02-28 Sensorion H4 receptor inhibitorok tinnitus kezelésére
ES2946551T3 (es) 2017-10-17 2023-07-20 Palau Pharma S L U Síntesis de compuestos de 4-aminopirimidina
GB201817047D0 (en) 2018-10-19 2018-12-05 Heptares Therapeutics Ltd H4 antagonist compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2361869C2 (ru) * 2002-02-05 2009-07-20 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Новые арил- и гетероарилпиперазины
EP1505064A1 (en) * 2003-08-05 2005-02-09 Bayer HealthCare AG 2-Aminopyrimidine derivatives
WO2005054239A1 (en) * 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
CA2551944A1 (en) * 2003-12-15 2005-06-30 Almirall Prodesfarma Ag 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists
DE602006020864D1 (de) * 2005-04-11 2011-05-05 Almirall Sa 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten
US20090306038A1 (en) * 2005-09-13 2009-12-10 Carceller Gonzalez Elena 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity
WO2007084914A2 (en) * 2006-01-17 2007-07-26 Neurocrine Biosciences, Inc. Phenoxy-substituted pyrimidines as adenosine receptor antagonists

Also Published As

Publication number Publication date
CN101903385B (zh) 2013-11-06
PE20091330A1 (es) 2009-09-07
IL206413A (en) 2015-06-30
WO2009080721A2 (en) 2009-07-02
JP2011506566A (ja) 2011-03-03
PT2235012E (pt) 2013-08-28
CL2008003811A1 (es) 2009-05-22
US8431580B2 (en) 2013-04-30
KR101639819B1 (ko) 2016-07-14
EP2235012B1 (en) 2013-07-17
ZA201005179B (en) 2012-03-28
BRPI0820779A2 (pt) 2015-06-16
AU2008341678A1 (en) 2009-07-02
CA2709650A1 (en) 2009-07-02
WO2009080721A3 (en) 2009-09-11
TW200938197A (en) 2009-09-16
UA101963C2 (en) 2013-05-27
TWI429440B (zh) 2014-03-11
SI2235012T1 (sl) 2013-11-29
PL2235012T3 (pl) 2013-12-31
KR20100096184A (ko) 2010-09-01
AU2008341678B2 (en) 2013-03-21
BRPI0820779B8 (pt) 2021-05-25
EP2235012A2 (en) 2010-10-06
CA2709650C (en) 2016-06-07
RU2010130418A (ru) 2012-01-27
CY1114427T1 (el) 2016-08-31
ES2430210T3 (es) 2013-11-19
DK2235012T3 (da) 2013-10-07
HRP20130918T1 (hr) 2013-11-08
BRPI0820779B1 (pt) 2020-02-04
US20110039817A1 (en) 2011-02-17
RU2489430C2 (ru) 2013-08-10
HK1149003A1 (en) 2011-09-23
CN101903385A (zh) 2010-12-01
IL206413A0 (en) 2010-12-30
AR069814A1 (es) 2010-02-17

Similar Documents

Publication Publication Date Title
JP7675777B2 (ja) 免疫調節剤としての複素環式化合物
JP2011506566A (ja) ヒスタミンｈ４受容体アンタゴニストとしての４−アミノピリミジン誘導体
US9758526B2 (en) Quinoline-substituted compound
JP6431593B2 (ja) ピリジニルアミノピリミジン誘導体、その製造方法、および用途
CN109761960B (zh) 抗耐药抗肿瘤egfr抑制剂的制备方法
WO2009068512A1 (en) 2 -amino-pyrimidine derivatives as histamine h4 antagonists
WO2009077608A1 (en) 2 -aminopyrimidine derivatives as histamine h4 antagonists
JP2009507896A (ja) ヒスタミンｈ４受容体活性の調節剤としての２−アミノピリミジン誘導体
KR101740085B1 (ko) 히스타민 ｈ４ 수용체 길항제로서의 아미노알킬피리미딘 유도체
WO2009115496A1 (en) Furo [3, 2-d] pyrimidine derivatives as h4 receptor antagonists
HK1149003B (en) 4-aminopyrimidine derivatives as histamine h4 receptor antagonists
WO2010094721A1 (en) Piperidin-pyrimidine derivatives as antagonists of histamine h4 receptor
HK1178162A (en) Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131021

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131121

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131212

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140307

R150 Certificate of patent or registration of utility model

Ref document number: 5498396

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250